[Treatment of lepromatous Hansen disease with a rifampicine-isoprodian association (author's transl)].
Thirty lepromatous patients were treated during 3 months. If clinical condition was notably improved, the bacillary index and the morphologic index remained almost un-changed and the histo-pathological features, advanced concurrently to the clinic aspects.
D003622:Dapsone / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D007539:Isonicotinic Acids / Q000627:therapeutic use*; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D009166:Mycobacterium leprae / Q000187:drug effects; D011515:Prothionamide / Q000627:therapeutic use*; D012293:Rifampin / Q000627:therapeutic use*; D012867:Skin / Q000473:pathology
D004338:Drug Combinations; D007539:Isonicotinic Acids; D007917:Leprostatic Agents; C011004:isoprodian; D011515:Prothionamide; D003622:Dapsone; D007538:Isoniazid; D012293:Rifampin
Traitement de la maladie de Hansen lépromateuse par l'association de rifampicine et d'isoprodian.